Business Standard

Alembic Pharma rises 3% as JV firm successfully completes USFDA inspection

The inspection was carried out from January 6 to January 8.

Bonds, Stock markets, Shares, Trading
Premium

SI Reporter New Delhi
Shares of Alembic Pharmaceuticals climbed up to nearly 3 per cent on the BSE in the early trade Thursday, a day after the company said its joint venture firm Aleor Dermaceuticals has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat without any observations. The inspection was carried out from January 6 to January 8. Click to read press release

Aleor Dermaceuticals is a 60:40 Joint Venture (JV) between Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies.

At 09:49 am, the stock was trading around 2 per cent higher at

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in